Aberdeen Group’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-616,413
Closed -$3.25M 932
2025
Q4
$3.25M Buy
+616,413
New +$3.1M 0.01% 739
2025
Q2
Sell
-224,356
Closed -$1.07M 951
2025
Q1
$1.07M Hold
224,356
﹤0.01% 813
2024
Q4
$1.25M Sell
224,356
-102,639
-31% -$632K ﹤0.01% 806
2024
Q3
$2.07M Buy
326,995
+200,647
+159% +$1.05M ﹤0.01% 754
2024
Q2
$536K Buy
+126,348
New +$645K ﹤0.01% 859

Other funds holding ABEO

Aberdeen Group's ABEO Position: Q1 2026 in Review

Aberdeen Group sold out of Abeona Therapeutics (ABEO) in Q1 2026, closing a stake of 616,413 shares — an estimated $3.25M sold.

Aberdeen Group first reported a position in ABEO in Q2 2024 and held it in 5 quarters. The position peaked at $3.25M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Aberdeen Group reported no remaining Abeona Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aberdeen Group sold 616,413 Abeona Therapeutics shares in Q1 2026, an estimated $3.25M.
  • Aberdeen Group first reported a position in Abeona Therapeutics in Q2 2024 and held it in 5 quarters.
  • Aberdeen Group's Abeona Therapeutics position peaked at $3.25M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.